AACR 2019 - Keep An Eye On These Biotech Stocks

(RTTNews) - The American Association for Cancer Research Annual Meeting 2019, which is the 110th Annual Meeting of the organization, kicked off on March 29th in Atlanta, Georgia. This 6-day annual meeting, which closes on April 3rd, highlights the best cancer science and medicine from institutions all over the world and is attended by academics, scientists, pharmaceutical industry representatives, patients, and patient advocates from across the globe.

The following are some of the companies making poster presentations at the AACR Annual Meeting.

1. Advaxis Inc. (ADXS)

Advaxis is a late-stage biotechnology company developing immunotherapy products. The Company has four programs in various stages of clinical development - ADXS-HPV for cervical cancer; ADXS-NEO for multiple cancers; ADXS-503 for non-small cell lung cancer and ADXS-PSA for prostate cancer.

Watch out for...

The updated clinical and biomarker data from a phase I/II study of ADXS-PSA in combination with KEYTRUDA in metastatic castration-resistant prostate cancer patients is slated to be presented on April 1.

ADXS closed Friday's trading at $5.91, up 3.54%.

2. Autolus Therapeutics plc (AUTL)

Autolus is a UK-based clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies.

The Company's pipeline includes:

-- AUTO1, under a phase I/II trial in patients with pediatric relapsed or refractory acute B lymphocytic leukemia, or pediatric ALL, dubbed CARPALL, and a phase I/II clinical trial in adult patients with ALL, dubbed ALLCAR19 study. -- AUTO2, under a phase I/II clinical trial in relapsed or refractory multiple myeloma. -- AUTO3, under phase I/II clinical trials in diffuse large B-cell lymphoma, and pediatric ALL.

Watch out for...

Initial data on the AUTO1 ALLCAR19 phase I/II trial in adult acute lymphoblastic leukemia, dubbed ALLCAR19 study, is expected to be presented on April 1.

AUTL closed Friday's trading at $31.47, up 4.07%.

3. Constellation Pharmaceuticals Inc. (CNST)

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.

The Company's clinical programs include CPI-0610, under a phase II trial in myelofibrosis, dubbed MANIFEST, and CPI-1205 in combination with either abiraterone or enzalutamide in metastatic castration-resistant prostate cancer, under a phase Ib/II trial, dubbed ProSTAR.

Watch out for...

The updated data from the phase Ib portion of the ProSTAR trial for CPI-1205 is expected to be presented on April 1.

CNST closed Friday's trading at $13.55, up 0.74%.

4. Dynavax Technologies Corp. (DVAX)

Dynavax is a commercial-stage fully-integrated biopharmaceutical company developing novel vaccines and immuno-oncology therapeutics.

The Company has 1 marketed product HEPLISAV-B, indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and a couple of products in clinical development, say, SD-101, under phase II trial in a variety of cancer indications, and DV281, under a phase 1b/2 clinical trial in subjects with advanced non-small cell lung cancer as monotherapy and in combination with OPDIVO.

Watch out for...

The safety and biomarker data from the phase 1b/2 clinical trial for DV281 in combination with OPDIVO in subjects with advanced non-small cell lung cancer are expected to be presented on April 2.

DVAX closed Friday's trading at $7.31, up 2.81%.

5. Jounce Therapeutics Inc. (JNCE)

Jounce Therapeutics. is a clinical-stage immunotherapy company developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients.

The Company's lead product candidate is Vopratelimab, formerly called JTX-2011, in a phase II portion of phase I/II trial in patients with solid tumors in both monotherapy and combination settings, dubbed ICONIC; JTX-4014, under a phase I dose escalation clinical study in adult subjects with advanced refractory solid tumor malignancies, and JTX-8064, which is in preclinical testing.

Watch out for...

New data from the phase I/II ICONIC trial evaluating JTX-2011 monotherapy and in combination with Opdivo is slated for presentation on April 2.

The Company presented the ICONIC trial data at the American Society for Clinical Oncology (ASCO) Annual Meeting in June 2018 and the Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November 2018.

The new data to be presented at the AACR Annual meeting shows improved progression free survival and overall survival in ICONIC patients who have emergence of ICOS hi CD4 T cells, according to the Company.

JNCE closed Friday's trading at $6.20, up 0.65%.

6. Neon Therapeutics Inc. (NTGN)

Neon is a clinical-stage immuno-oncology company developing neoantigen-targeted therapies for cancers.

The Company's most advanced product candidate is NEO-PV-01, a personal neoantigen vaccine, under phase Ib trials, dubbed NT-001, NT-002, NT-003, and NT-004.

Watch out for...

The updated correlative data from the NT-001 trial is expected to be presented on April 3. In the NT-001 trial, the combination of NEO-PV-01 and Bristol Myers' Opdivo in patients with metastatic or advanced melanoma, lung, or bladder cancer, is being tested.

NTGN closed Friday's trading at $6.46, up 5.38%.

7. Trovagene Inc. (TROV)

Trovagene is a clinical-stage oncology therapeutics company.

The Company's lead product candidate is Onvansertib being tested in combination with either low-dose cytarabine (LDAC) or decitabine for the treatment of Acute Myeloid Leukemia (AML) under a phase Ib/II trial, and in combination with Zytiga for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) in a phase II trial.

Watch out for...

Safety and preliminary clinical data from the phase Ib/II trial in AML and phase II trial in mCRPC are expected to be presented on April 1 and April 2, respectively.

TROV closed Friday's trading at $3.75, up 3.02%.